Genomic Valley Biotech share news and announcements
BSE: 539206Pharmaceuticals & BiotechnologySmall Cap
Last close ₹37.71up ₹1.79 (4.98%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹35.92.
52-week range of traded prices to 23 Oct 2026
₹20.10Low, 29 Jan 2026₹38.20High, 6 Nov 2025
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹12 Cr4,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 15 Aug 2026
- 567.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 2.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 15 Aug 2026
- 0.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 15 Aug 2026
- 0.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,994
Genomic Valley Biotech share news and announcements
489 announcements, routine notices left out, newest first. Page 3 of 10.
Nov 2023
8 Nov · Board meeting
Meeting on 14 Nov 2023: quarterly results
Sep 2023
30 Sep · Management
30 Sep · Management
30 Sep · Meeting
5 Sep · Corporate action
4 Sep · Board meeting
4 Sep · Board meeting
Aug 2023
8 Aug · Board meeting
Meeting on 14 Aug 2023: quarterly results
Jun 2023
30 Jun · Board meeting
Meeting on 30 Jun 202330 Jun · Management
30 Jun · Management
30 Jun · Management
30 Jun · Management
30 Jun · Board meeting
May 2023
23 May · Board meeting
Meeting on 29 May 2023: audited results and quarterly results
Apr 2023
26 Apr · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Mar 2023
31 Mar · Board meeting
Meeting on 31 Mar 202331 Mar · Management
31 Mar · Management
31 Mar · Management
31 Mar · Management
31 Mar · Management
31 Mar · Board meeting
Feb 2023
10 Feb · Management
10 Feb · Management
2 Feb · Board meeting
Meeting on 10 Feb 2023: quarterly results